"We are excited to host the Scientific Symposium again this year” said Uma Sharma, Ph.D., Chief Scientific Officer at MMS Holdings.
“Our goal for this event is to bring together scientific minds for a fruitful discussion on topics that affect us all in the pharmaceutical and biotech industries."
The complimentary event is open to all individuals in the pharmaceutical and biotech arenas. Registration is currently open and limited to the first 150 registrants. Presenters for the symposium include some of the top innovators in pharma.
Presentations include:
- Challenges in Conducting Pain Trials: A Sponsor’s Perspective by Nico Merante, Senior Director of Clinical Development at Daiichi Sankyo Development Ltd.
- Quantitative Decision Making: No Longer a Simple Yes or No Question by Kevin Chartier, Global Franchise Head at Novartis Pharmaceuticals Corporation.
- Trends, Needs and Next Steps in the Evolving Regulations of Clinical Trial Disclosures by Joe Archer, Associate Director, Disclosure Services at MMS Holdings Inc.
- Regulatory Mechanisms to Speed Access to Medicines: A Worldwide Overview by Mark Ammann and Lisa Rysso-DeMaggio, Regulatory Strategy for MMS Holdings Inc.
To register for the 2012 Scientific Symposium go to: http://blog.mmsholdings.com/annual-scientific-symposium-2012
MMS Holdings Inc. is a highly experienced pharmaceutical service organization, based in Canton Michigan, that is focused on quality deliverables in the areas of clinical programming, biostatistics, medical and regulatory writing, pharmacovigilance, clinical trial disclosure, data abstraction, and data management. Commitment to quality deliverables with robust submission experience sets MMS apart from traditional service providers. MMS Holdings Inc. is ISO 9001:2008 certified for all services and maintains detailed quality metrics for every project.
For more information visit http://www.mmsholdings.com. Join the conversation on Twitter using #MASS12
